PD-L1: Biological Mechanism, Function, and Immunotherapy in Gastric Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 12

PMID 36505487

Authors

Yingzi Zhang

Yan Yang

Yiran Chen

Wu Lin

Xiangliu Chen

Jin Liu

Yingying Huang

Haiyong Wang

Lisong Teng

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune efficacy. Further understanding of the regulatory mechanism of PD-L1 in GC may bring substantial progress to the immunotherapy. In this review, we provide information on the endogenous and exogenous regulatory mechanisms of PD-L1 and its biological functions combined with current clinical trials of PD-L1/PD-1 inhibitors in GC. The malignant biological phenotypes caused by PD-L1 and the corresponding clinical combined treatment scheme have been reported. Identifying the biomarkers of the potential efficacy of immunotherapy and specifying the clinical immunotherapy scheme in combination with molecular characteristics of patients may maximize clinical benefits and better prognosis.

Citing Articles

Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer.

He X, Guan X, Li Y Front Immunol. 2025; 16:1532605.

PMID: 40028336 PMC: 11868122. DOI: 10.3389/fimmu.2025.1532605.

Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.

Li L, Yu A, Zhu M, Ma L, Cao M, Liu W Arch Virol. 2024; 169(5):114.

PMID: 38700535 DOI: 10.1007/s00705-024-06033-3.

Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model.

He X, Du B, Wu T, Shen H World J Gastrointest Oncol. 2024; 16(4):1268-1280.

PMID: 38660670 PMC: 11037037. DOI: 10.4251/wjgo.v16.i4.1268.

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.

Ren X, Wang L, Liu L, Liu J Front Immunol. 2024; 15:1392546.

PMID: 38638430 PMC: 11024247. DOI: 10.3389/fimmu.2024.1392546.

Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.

Wang X, Liu X, Dai H, Jia J BMC Gastroenterol. 2024; 24(1):113.

PMID: 38491354 PMC: 10943815. DOI: 10.1186/s12876-024-03168-0.

References

Saeed A, Park R, Sun W . The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. J Hematol Oncol. 2021; 14(1):13. PMC: 7802258. DOI: 10.1186/s13045-021-01034-0. View

Ju X, Zhang H, Zhou Z, Chen M, Wang Q . Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling. Exp Cell Res. 2020; 396(2):112315. DOI: 10.1016/j.yexcr.2020.112315. View

Li C, Qiu J, Xue Y . Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC). Cell Biosci. 2021; 11(1):38. PMC: 7881658. DOI: 10.1186/s13578-021-00548-x. View

Amini M, Hejazi M, Ghorban K, Mokhtarzadeh A, Baradaran B . Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer. Gene. 2020; 772:145376. DOI: 10.1016/j.gene.2020.145376. View

Zhang D, He W, Wu C, Tan Y, He Y, Xu B . Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. Front Immunol. 2019; 10:71. PMC: 6361780. DOI: 10.3389/fimmu.2019.00071. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Shevtsov M, Sato H, Multhoff G, Shibata A . Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. Front Oncol. 2019; 9:156. PMC: 6433964. DOI: 10.3389/fonc.2019.00156. View

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

Herter-Sprie G, Koyama S, Korideck H, Hai J, Deng J, Li Y . Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016; 1(9):e87415. PMC: 5033933. DOI: 10.1172/jci.insight.87415. View

10.

Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins J, Ito Y . Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021; 518:59-71. PMC: 8606306. DOI: 10.1016/j.canlet.2021.06.007. View

11.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

12.

Li P, Luo X, Xie Y, Li P, Hu F, Chu J . GC-Derived EVs Enriched with MicroRNA-675-3p Contribute to the MAPK/PD-L1-Mediated Tumor Immune Escape by Targeting CXXC4. Mol Ther Nucleic Acids. 2020; 22:615-626. PMC: 7578556. DOI: 10.1016/j.omtn.2020.08.020. View

13.

Fu L, Fan J, Maity S, McFadden G, Shi Y, Kong W . PD-L1 interacts with Frizzled 6 to activate β-catenin and form a positive feedback loop to promote cancer stem cell expansion. Oncogene. 2022; 41(8):1100-1113. DOI: 10.1038/s41388-021-02144-2. View

14.

Yan X, Luo Q, Zhou S, Pan W, Zhang L, Yang D . MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clin Res Hepatol Gastroenterol. 2020; 45(5):101574. DOI: 10.1016/j.clinre.2020.10.015. View

15.

Yoon C, Chang M, Kim D, Kim W, Koo B, Yun S . Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas. Gastric Cancer. 2020; 23(5):780-795. DOI: 10.1007/s10120-020-01059-3. View

16.

Ott P, Bang Y, Piha-Paul S, Abdul Razak A, Bennouna J, Soria J . T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2018; 37(4):318-327. DOI: 10.1200/JCO.2018.78.2276. View

17.

Meric-Bernstam F, Larkin J, Tabernero J, Bonini C . Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2020; 397(10278):1010-1022. DOI: 10.1016/S0140-6736(20)32598-8. View

18.

Wang X, Wu W, Gao J, Li Z, Dong B, Lin X . Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res. 2019; 38(1):140. PMC: 6440013. DOI: 10.1186/s13046-019-1148-5. View

19.

Fang W, Chang S, Lan Y, Huang K, Chen J, Lo S . Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 2012; 36(9):2131-8. DOI: 10.1007/s00268-012-1652-7. View

20.

Yap T, Parkes E, Peng W, Moyers J, Curran M, Tawbi H . Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021; 11(6):1368-1397. PMC: 8178168. DOI: 10.1158/2159-8290.CD-20-1209. View